FCGR2A and neoplasm: Interestingly, it has recently been shown in a murine tumor model that anti-PD-1/PD-L1 antibodies differ in their FcγR requirements for optimal activity: FcγR engagement compromises the anti-tumor activity of anti-PD-1 antibodies, but binding to activating FcγR augments the anti-tumor effects of anti-PD-L1 antibodies (13).